These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 37941651)

  • 41. Neuroendocrine Differentiation of Prostate Cancer-An Intriguing Example of Tumor Evolution at Play.
    Patel GK; Chugh N; Tripathi M
    Cancers (Basel); 2019 Sep; 11(10):. PubMed ID: 31547070
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Downregulation of
    Russo JW; Gao C; Bhasin SS; Voznesensky OS; Calagua C; Arai S; Nelson PS; Montgomery B; Mostaghel EA; Corey E; Taplin ME; Ye H; Bhasin M; Balk SP
    Cancer Res; 2018 Nov; 78(22):6354-6362. PubMed ID: 30242112
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The tumor microenvironment as driver of stemness and therapeutic resistance in breast cancer: New challenges and therapeutic opportunities.
    Mehraj U; Ganai RA; Macha MA; Hamid A; Zargar MA; Bhat AA; Nasser MW; Haris M; Batra SK; Alshehri B; Al-Baradie RS; Mir MA; Wani NA
    Cell Oncol (Dordr); 2021 Dec; 44(6):1209-1229. PubMed ID: 34528143
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancer.
    Armstrong AJ; Gupta S; Healy P; Kemeny G; Leith B; Zalutsky MR; Spritzer C; Davies C; Rothwell C; Ware K; Somarelli JA; Wood K; Ribar T; Giannakakou P; Zhang J; Gerber D; Anand M; Foo WC; Halabi S; Gregory SG; George DJ
    PLoS One; 2019; 14(5):e0216934. PubMed ID: 31136607
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cytoskeleton targeting value in prostate cancer treatment.
    Martin SK; Kamelgarn M; Kyprianou N
    Am J Clin Exp Urol; 2014; 2(1):15-26. PubMed ID: 25374905
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Castration-resistant prostate cancer: potential targets and therapies.
    Parray A; Siddique HR; Nanda S; Konety BR; Saleem M
    Biologics; 2012; 6():267-76. PubMed ID: 22956858
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The role of actinin-4 (ACTN4) in exosomes as a potential novel therapeutic target in castration-resistant prostate cancer.
    Ishizuya Y; Uemura M; Narumi R; Tomiyama E; Koh Y; Matsushita M; Nakano K; Hayashi Y; Wang C; Kato T; Hatano K; Kawashima A; Ujike T; Fujita K; Imamura R; Adachi J; Tomonaga T; Nonomura N
    Biochem Biophys Res Commun; 2020 Mar; 523(3):588-594. PubMed ID: 31941606
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Alterations of tumor microenvironment by nitric oxide impedes castration-resistant prostate cancer growth.
    Arora H; Panara K; Kuchakulla M; Kulandavelu S; Burnstein KL; Schally AV; Hare JM; Ramasamy R
    Proc Natl Acad Sci U S A; 2018 Oct; 115(44):11298-11303. PubMed ID: 30322928
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
    Martin SK; Kyprianou N
    Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Epigenetic modulations and lineage plasticity in advanced prostate cancer.
    Ge R; Wang Z; Montironi R; Jiang Z; Cheng M; Santoni M; Huang K; Massari F; Lu X; Cimadamore A; Lopez-Beltran A; Cheng L
    Ann Oncol; 2020 Apr; 31(4):470-479. PubMed ID: 32139297
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles.
    Hoang DT; Iczkowski KA; Kilari D; See W; Nevalainen MT
    Oncotarget; 2017 Jan; 8(2):3724-3745. PubMed ID: 27741508
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Multifaceted Roles for Macrophages in Prostate Cancer Skeletal Metastasis.
    Lo CH; Lynch CC
    Front Endocrinol (Lausanne); 2018; 9():247. PubMed ID: 29867776
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment.
    Subudhi SK; Siddiqui BA; Aparicio AM; Yadav SS; Basu S; Chen H; Jindal S; Tidwell RSS; Varma A; Logothetis CJ; Allison JP; Corn PG; Sharma P
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34663638
    [TBL] [Abstract][Full Text] [Related]  

  • 54.
    Fararjeh AS; Liu YN
    Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31181727
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Epithelial-to-Mesenchymal Transition-Related Markers in Prostate Cancer: From Bench to Bedside.
    Gogola S; Rejzer M; Bahmad HF; Abou-Kheir W; Omarzai Y; Poppiti R
    Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190236
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Macrophage-Derived Cholesterol Contributes to Therapeutic Resistance in Prostate Cancer.
    El-Kenawi A; Dominguez-Viqueira W; Liu M; Awasthi S; Abraham-Miranda J; Keske A; Steiner KK; Noel L; Serna AN; Dhillon J; Gillies RJ; Yu X; Koomen JM; Yamoah K; Gatenby RA; Ruffell B
    Cancer Res; 2021 Nov; 81(21):5477-5490. PubMed ID: 34301759
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mechanisms of resistance in castration-resistant prostate cancer (CRPC).
    Chandrasekar T; Yang JC; Gao AC; Evans CP
    Transl Androl Urol; 2015 Jun; 4(3):365-80. PubMed ID: 26814148
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Myeloid differentiation factor-2/LY96, a new predictive biomarker of metastasis in prostate cancer: Clinical implications as a potential therapeutic target.
    Ferrari M; Wang L; Hoeppner L; Hahm E; Yu J; Kuzel T; Mansini A
    Res Sq; 2023 Jun; ():. PubMed ID: 37333086
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Abiraterone in the treatment of metastatic castration-resistant prostate cancer.
    Mostaghel EA
    Cancer Manag Res; 2014; 6():39-51. PubMed ID: 24501545
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Recent advances on the progressive mechanism and therapy in castration-resistant prostate cancer.
    Wang K; Ruan H; Xu T; Liu L; Liu D; Yang H; Zhang X; Chen K
    Onco Targets Ther; 2018; 11():3167-3178. PubMed ID: 29881290
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.